Given that we documented a 33% reduction of CPLX1 expression in blood of presymptomatic PARK4 individuals, the dysregulation appears to be relatively stable over decades and might not be useful as a biomarker of disease progression from the prodromal to the final stages of PD. The gene discussed is CPLX1; the disease is Parkinson disease.